Navigation Links
Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Date:4/1/2008

Reflects Full Scope of Integrated Global Services

CAMBRIDGE, Mass., April 1, 2008 /PRNewswire/ -- Abt Associates Clinical Trials today launches under a new name, Abt Bio-Pharma Solutions, Inc., a wholly owned subsidiary of Abt Associates Inc. The company will continue to provide custom strategic, research and communication solutions for the pharmaceutical, biotechnology, medical device and diagnostics industries utilizing a team approach that blends decades of experience with wide ranging technical and therapeutic area expertise.

Abt Bio-Pharma Solutions (ABS) offers a wide range of integrated services across the product lifecycle, including health economics and outcomes research, registries and other real world studies, clinical trials, biometrics and marketing consulting and research. Experienced professional staff lead cross-functional teams that are better able to address the complex issues facing the bio-pharma industry. Sponsors find that this integrated, collaborative approach promotes cost- and time-effective solutions to their business problems, with the result that the organization has grown 30 percent over the past year.

"ABS helps sponsors achieve success for their products in a very competitive marketplace," said Steven Fosburg, Executive Vice President and Managing Director of ABS. "We will leverage the increased flexibility that our new organization affords to invest in staff and resources to meet the expanding needs of our global client base without sacrificing any of the scientific rigor or timeliness that we are known for." ABS will open an office in Basel, Switzerland in May 2008.

Abt Associates has been a leader in healthcare-related research since 1965. "Abt Associates has a strong commitment to improving the health of people and communities around the world," said Wendell J. Knox, President and CEO of Abt Associates. "Abt Bio-Pharma Solutions is well positioned to respond to the clinical research and marketing challenges our clients face as they bring new products and solutions to market." As a subsidiary of Abt Associates, ABS is able to call on the company's extensive research services, knowledge base and technical expertise.

Abt Associates applies scientific research, technical assistance and consulting expertise to a wide range of social, economic and health policy issues; international development; bio-pharma industry issues; and complex business problems. Founded in 1965, the company provides services to U.S. federal, state and local governments; universities and foundations; media; and major corporations. Its staff of over 1,000 is located in Cambridge, Lexington (Abt Bio-Pharma Solutions, Inc.), and Hadley, Massachusetts; Bethesda, Maryland; Durham, North Carolina; Chicago Illinois; New York, New York (SRBI), and in Africa, Asia, Central Asia, Europe, Latin America, and the Middle East.


'/>"/>
SOURCE Abt Associates
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
Breaking Biology News(10 mins):